more

Sanofi (SNY)

(Delayed Data from NSDQ)

$56.33 USD

+0.22 (0.39%)

Updated Aug 29, 2024 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank	Definition	Annualized Return
1	Strong Buy	23.68%
2	Buy	17.55%
3	Hold	9.21%
4	Sell	4.93%
5	Strong Sell	2.36%
S&P	500	10.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5 3

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score	A
Growth Score	A
Momentum Score	A
VGM Score	A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value B Growth B Momentum A VGM

Industry Rank:

Top 38% (95 out of 251)

Industry: Large Cap Pharmaceuticals

View All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

What's in the Cards for Amarin (AMRN) This Earnings Season?

by Zacks Equity Research Published on February 20,2020

Amarin's (AMRN) fourth-quarter results are likely to reflect strong demand for its cardiovascular drug, Vascepa.

pharmaceuticals

Sanofi, J&J Join Forces With BARDA for Coronavirus Vaccine

by Zacks Equity Research Published on February 19,2020

Sanofi (SNY) and J&J (JNJ) sign deals with BARDA, part of U.S. Department of Health and Human Services, for accelerated development of a vaccine for the newly found coronavirus.

pharmaceuticals

Top Research Reports for Facebook, Netflix & NextEra Energy

by Sheraz Mian Published on February 19,2020

Today's Research Daily features new research reports on 16 major stocks, including Facebook (FB), Netflix (NFLX) and NextEra Energy (NEE).

Regeneron Reports Positive Eylea Data From Late-Stage Study

by Zacks Equity Research Published on February 10,2020

Regeneron (REGN) announces positive two-year results from the phase III PANORAMA study on lead ophthalmology drug, Eylea.

biotechs

Pharma Stock Roundup: BMY, GSK, SNY Q4 Results, MRK Earnings & Split

by Kinjel Shah Published on February 07,2020

Merck (MRK), Bristol Myers (BMY), Sanofi (SNY), Glaxo (GSK) and Novo Nordisk (NVO) announce Q4 results.

pharmaceuticals

Alnylam's (ALNY) Q4 Earnings Miss Estimates, Sales Beat

by Zacks Equity Research Published on February 07,2020

Alnylam (ALNY) posts a wider-than-expected loss, while revenues beat estimates marginally in the fourth quarter of 2019.

biotechs

Sanofi (SNY) Q4 Earnings Top, Sales Miss, Dupixent Strong

by Zacks Equity Research Published on February 06,2020

Sanofi (SNY) reports mixed fourth-quarter results with strong Specialty Care and Vaccines sales but soft Consumer Healthcare sales

pharmaceuticals

Regeneron's (REGN) Q4 Earnings & Sales Surpass Estimates

by Zacks Equity Research Published on February 06,2020

Regeneron (REGN) beats on Q4 earnings and sales on solid performance of ophthalmology drug, Eylea, and asthma drug, Dupixent.

Novo Nordisk (NVO) Q4 Earnings Match Estimates, Revenues Beat

by Zacks Equity Research Published on February 05,2020

Novo Nordisk (NVO) posts in-line earnings, while revenues beat estimates in the fourth quarter of 2019.

pharmaceuticals

Why Earnings Season Could Be Great for Sanofi (SNY)

by Zacks Equity Research Published on February 05,2020

Sanofi (SNY) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

SNYPositive Net Change

medical

Merck (MRK) Beats on Q4 Earnings, Plans Women Health Spin Off

by Zacks Equity Research Published on February 05,2020

Merck (MRK) beats estimates for earnings but misses the same for sales in fourth-quarter 2019. The company plans to spin off Women Health drugs/biosimilars into new company. Shares down.

pharmaceuticals

Merck's Recarbrio Gets FDA Priority Review for New Indication

by Zacks Equity Research Published on February 04,2020

The FDA accepts Merck's (MRK) sNDA for antibacterial injection Recarbrio and grants priority review.

pharmaceuticals

Will Eylea & Dupixent Drive Regeneron's (REGN) Q4 Earnings?

by Zacks Equity Research Published on February 03,2020

Investors will focus on the performance of Eylea and Dupixent along with other pipeline updates, when Regeneron (REGN) reports fourth-quarter 2019 results.

biotechs

Lilly's NDA for Selpercatinib Gets FDA's Priority Review

by Zacks Equity Research Published on January 30,2020

Lilly's (LLY) NDA for oral RET inhibitor selpercatinib gains the FDA priority review status for RET-altered lung and thyroid cancers.

pharmaceuticals

Biotech Stock Roundup: EPZM Drug Gets FDA Nod, XLRN & HEPA Surge on Study Data

by Zacks Equity Research Published on January 29,2020

It has been a busy week for the biotech sector with pipeline and regulatory updates from quite a few players.

biotechs

Are Investors Undervaluing Sanofi (SNY) Right Now?

by Zacks Equity Research Published on January 28,2020

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.